期刊文献+

三阴乳腺癌Ki-67的表达与ER、PR及Her-2的关系研究 被引量:1

The expression of Ki-67 in triple-negative breast cancer and its relationship with ER, PR and Her-2
下载PDF
导出
摘要 目的:对Ki-67在三阴性乳腺癌中的表达情况进行研究,并探讨Ki-67与临床病理特征的关系及雌激素受体(ER)、孕激素受体(PR)、人表皮生长因子受体(Her-2)基因表达间的相关性及临床意义,为临床中乳腺癌的预后判断提供依据,并指导个体化治疗。方法以2012年4月—2014年12月在我院治疗的189例乳腺癌患者为研究对象,其中三阴乳腺癌34例,非三阴乳腺癌155例,采用免疫组织化学法检测189例乳腺癌标本中Ki-67及ER、PR、Her-2的表达。结果 Ki-67在淋巴结有无转移的2组不同乳腺癌组织中的表达差异均有统计学意义,在淋巴结转移的乳腺癌组织中Ki-67的表达阳性率明显高于非淋巴结转移的乳腺癌组织( P<0.05);Ki-67在乳腺癌组织中的表达强度与Her-2的表达强度呈正相关;Ki-67在乳腺癌中的表达强度与激素受体ER、PR表达强度呈负相关。结论 Ki-67分子标志物在三阴性乳腺癌中的表达水平高,乳腺癌中Ki-67的阳性表达提示患者淋巴转移的可能性大。乳腺癌的Ki-67的表达与Her-2基因蛋白表达阳性、激素受体ER、PR阴性表达呈正相关。 Objective To investigate the expression of Ki-67 in triple-negative breast cancer and its relationship with pathological features and estrogen receptor ( ER) , progesterone receptor ( PR) and human epidermal growth factor receptor 2 ( Her-2 ) , in order to provide evidence for clinical prognosis of breast cancer.Methods A total of 189 breast cancer patients were enrolled into the current, who were admitted into our hospital from April 2012 to December 2014.Among them were 34 patients with triple-negative breast cancer and 155 ones with non-triple-negative breast cancer.Then, breast cancer tissue samples were harvested from each patient to measure the levels of Ki-67, ER, PR, and Her-2 by immunohistochemistry.Results Breast cancer tissues with lymph node metastasis showed a significantly higher positive rate of Ki-67 than that of breast cancer tissues without lymph node metastasis ( P〈0.05) .The level of Ki-67 in breast cancer was positively associated with Her-2 expression, and negatively associated with the expression of ER and PR.Conclusion Ki-67 is highly expressed in triple-negative breast cancer, indicating more possibility of lymph node metastasis.The level of Ki-67 in breast cancer is positively associated with Her-2 expression and negative-ly associated with the amounts of ER and PR.
出处 《徐州医学院学报》 CAS 2015年第12期921-924,共4页 Acta Academiae Medicinae Xuzhou
关键词 三阴性乳腺癌 KI-67 雌激素受体 孕激素受体 人表皮生长因子受体 triple- negative breast cancer Ki- 67 estrogen receptor progesterone receptor human epidermal growth factor receptor 2
  • 相关文献

参考文献9

  • 1Sorlie T. Molecular classification of breast tumors: toward im- proved diagnostics and treatments [ J ]. Methods Mol Biol, 2007, 360:91 - 114.
  • 2Perou CM, Sodie T, Eisen MB, et al. Molecular portraits of hu- man breast tumors [ J]. Nature, 2000,406 (6797) :747 - 752.
  • 3Carey LA, Perou CM, Livasy CA, et al. Raee, breast cancer sub- types, and survival in the Carolina breast cancer study [ J ]. JA- MA, 2006,295(21 ) :2492 -24502.
  • 4Urrutieoeehea A, Smith IE, Dowsett M, et al. Proliferation mark- er Ki- 67 in early breast cancer [ J ]. J Clin Oncol, 2005,23 (28) :7212 - 7220.
  • 5Jones RL, Salter J, A' Hem R, et al. Relationship between oes- trogen receptor status and proliferation in predicting response and long - term outcome to neoadjuvant chemotherapy for breast cancer [J]. Breast Cancer Res Treat, 2010,119(2) :315 -323.
  • 6Keam B, Im SA, Kim HI, et al. Prognostie impaet of elinieopath- ologie parameters in stage Ⅱ/Ⅲ breast cancer treated with neoadju- rant doeetaxel and doxorubiein chemotherapy: paradoxieal features of the triple negative breast cancer [ J]. BMC Cancer, 2007,7: 203.
  • 7Molino A, Pedersini R, Micciolo R, et al. Relationship between the thymidine labeling and Ki - 67 proliferative indices in 126 breast cancer patients [ J ]. Appl Immunohistocheam Mol Mor- phol, 2002,10 (4) : 304 - 309.
  • 8Urruticoechea A, Smith IE, Dowsett M. Proliferation maker Ki - 67 in early breast cancer [J]. J Clin Oncol, 2005,23(28) :7212 - 7220.
  • 9Bottini A, Berruti A, Bersiga A, et al. Relationship between tumour shrinkage and reduction in Ki -67 expression after prima- ry chemotherapy in human breast cancer [ J]. Br J Cancer, 2001, 85(8) :1106 -1112.

同被引文献6

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部